Viral Hepatitis

You have full text access to this OnlineOpen article

Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study

  1. Jennifer K. King1,
  2. Shiou-Hwei Yeh2,3,
  3. Ming-Wei Lin4,5,
  4. Chun-Jen Liu6,7,
  5. Ming-Yang Lai6,7,
  6. Jia-Horng Kao6,7,
  7. Ding-Shinn Chen2,6,
  8. Pei-Jer Chen M.D., Ph.D. Professor and Director2,7,*

Article first published online: 7 MAR 2007

DOI: 10.1002/hep.1840360618

Issue

Hepatology

Hepatology

Volume 36, Issue 6, pages 1416–1424, December 2002

Additional Information

How to Cite

King, J. K., Yeh, S.-H., Lin, M.-W., Liu, C.-J., Lai, M.-Y., Kao, J.-H., Chen, D.-S. and Chen, P.-J. (2002), Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. Hepatology, 36: 1416–1424. doi: 10.1002/hep.1840360618

Author Information

  1. 1

    Harvard Medical School, Boston, MA

  2. 2

    Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

  3. 3

    Division of Molecular and Genomic Medicine, National Health Research Institutes, Taipei, Taiwan

  4. 4

    Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan

  5. 5

    Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan

  6. 6

    Department of Internal Medicine College of Medicine, National Taiwan University, Taipei, Taiwan

  7. 7

    Graduate Institute of Clinical Medicine, National Taiwan University, Taipei, Taiwan

*Hepatitis Research Center, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan. fax: (886) 2–2331–7624

Publication History

  1. Issue published online: 7 MAR 2007
  2. Article first published online: 7 MAR 2007
  3. Manuscript Accepted: 26 SEP 2002
  4. Manuscript Received: 31 MAY 2002

Funded by

  • Disease Control and National Health Research Institute

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (837K)

Reference

  • 1
    World Health Organization, 1998. Hepatitis B Fact Sheet WHO/204. http://www.who.int/inf-fs/en/fact203.html
  • 2
    Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Hallahan C, et al. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318–1325.
  • 3
    Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, Ma OC, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091–2097.
  • 4
    Alexander GJ, Brahm J, Fagan EA, Smith HM, Daniels HM, Eddleston AL, Williams R. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987; 2: 66–69.
  • 5
    Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347–356.
  • 6
    Lin OS, Keeffe EB. Current treatment strategies for chronic hepatitis B and C. Annu Rev Med 2001; 52: 29–49.
  • 7
    Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711–713.
    Direct Link:
  • 8
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714–717.
  • 9
    Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20–22.
  • 10
    Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002; 40: 1207–1209.
  • 11
    Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554–559.
  • 12
    Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998–1002.
  • 13
    Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999; 179: 775–782.
  • 14
    Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, Heintges T, Niederau C, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31: 716–725.
    Direct Link:
  • 15
    Zhang X, Zoulim F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HB e antigen negative chronic hepatitis B. J Med Virol 1996; 48: 8–16.
    Direct Link:
  • 16
    Hohler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, Lohr HF, et al. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol 1997; 26: 503–507.
  • 17
    Thursz MR, Kwiatkowski D, Allsopp CE, Greenwood BM, Thomas HC, Hill AV. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995; 332: 1065–1069.
  • 18
    McNicholl JM, Downer MV, Udhayakumar V, Alper CA, Swerdlow DL. Host-pathogen interactions in emerging and re-emerging infectious diseases: a genomic perspective of tuberculosis, malaria, human immunodeficiency virus infection, hepatitis B, and cholera. Annu Rev Public Health 2000; 21: 15–46.
  • 19
    Scully LJ, Brown D, Lloyd C, Shein R, Thomas HC. Immunological studies before and during interferon therapy in chronic HBV infection: identification of factors predicting response. Hepatology 1990; 12: 1111–1117.
    Direct Link:
  • 20
    Samuel CE. Antiviral actions of interferons [Table of Contents]. Clin Microbiol Rev 2001; 14: 778–809.
  • 21
    Darnell JE Jr. STATs and gene regulation. Science 1997; 277: 1630–1635.
  • 22
    Clayton D, Jones H. Transmission/disequilibrium teats for extended marker haplotypes. Am J Hum Genet 1999; 65: 1161–1169.
  • 23
    Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995; 59: 97–105.
    Direct Link:
  • 24
    Samuel CE. Mechanism of interferon action: phosphorylation of protein synthesis initiation factor eIF-2 in interferon-treated human cells by a ribosome-associated kinase processing site specificity similar to hemin-regulated rabbit reticulocyte kinase. Proc Natl Acad Sci U S A 1979; 76: 600–604.
  • 25
    Pathak VK, Schindler D, Hershey JW. Generation of a mutant form of protein synthesis initiation factor eIF-2 lacking the site of phosphorylation by eIF-2 kinases. Mol Cell Biol 1988; 8: 993–995.
  • 26
    Lindenbach BD, Rice CM, Clemens MJ. RNA in targeting an animal virus: news from the front. Initiation factor eIF2 a phosphorylation in stress responses and apoptosis. Mol Cell 2002; 9: 925–927.
  • 27
    Clemens MJ. Initiation factor eIF2 alpha phosphorylation in stress responses and apoptosis. Prog Mol Subcell Biol 2001; 27: 57–89.
  • 28
    Humbelin M, Safer B, Chiorini JA, Hershey JW, Cohen RB. Isolation and characterization of the promoter and flanking regions of the gene encoding the human protein-synthesis-initiation factor 2 α. Gene 1989; 81: 315–324.
  • 29
    Jacob WF, Silverman TA, Cohen RB, Safer B. Identification and characterization of a novel transcription factor participating in the expression of eukaryotic initiation factor 2 α. J Biol Chem 1989; 264: 20372–20384.
  • 30
    Noguchi M, Miyamoto S, Silverman TA, Safer B. Characterization of an antisense Inr element in the eIF-2 α gene. J Biol Chem 1994; 269: 29161–29167.
  • 31
    Silverman TA, Noguchi M, Safer B. Role of sequences within the first intron in the regulation of expression of eukaryotic initiation factor 2 α. J Biol Chem 1992; 267: 9738–9742.
  • 32
    Hijikata M, Mishiro S, Miyamoto C, Furuichi Y, Hashimoto M, Ohta Y. Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sizes (-123 and −88) in vivo and in vitro. Intervirology 2001; 44: 379–382.
  • 33
    Pavlovic J, Schroder A, Blank A, Pitossi F, Staeheli P. Mx proteins: GT-Pases involved in the interferon-induced antiviral state. Ciba Found Symp 1993; 176: 233–243.
  • 34
    Haller O, Frese M, Kochs G. Mx proteins: mediators of innate resistance to RNA viruses. Rev Sci Tech 1998; 17: 220–230.
  • 35
    Arnheiter H, Frese M, Kambadur R, Meier E, Haller O. Mx transgenic mice—animal models of health. Curr Top Microbiol Immunol 1996; 206: 119–147.
  • 36
    Frese M, Kochs G, Meier-Dieter U, Siebler J, Haller O. Human MxA protein inhibits tick-borne Thogoto virus but not Dhori virus. J Virol 1995; 69: 3904–3909.
  • 37
    Marschall M, Zach A, Hechtfischer A, Foerst G, Meier-Ewert H, Haller O. Inhibition of influenza C viruses by human MxA protein. Virus Res 2000; 67: 179–188.
  • 38
    Pavlovic J, Hailer O, Staeheli P. Human and mouse Mx proteins inhibit different steps of the influenza virus multiplication cycle. J Virol 1992; 66: 2564–2569.
  • 39
    Hijikata M, Ohta Y, Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt −88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000; 43: 124–127.
  • 40
    Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of α-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312–323.
  • 41
    Warrington JA, Shah NA, Chen X, Janis M, Liu C, Kondapalli S, Reyes V, et al. New developments in high-throughput resequencing and variation detection using high density microarrays. Hum Mutat 2002; 19: 402–409.
    Direct Link:
  • 42
    Huber M, Mundlein A, Dornstauder E, Schneeberger C, Tempfer CB, Mueller MW, Schmidt WM. Accessing single nucleotide polymorphisms in genomic DNA by direct multiplex polymerase chain reaction amplification on oligonucleotide microarrays. Ann Biochem 2002; 303: 25–33.
  • 43
    Fakhrai-Rad H, Pourmand N, Ronaghi M. Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms. Hum Mutat 2002; 19: 479–485.
    Direct Link:
  • 44
    Kwok PY. Methods for genotyping single nucleotide polymorphisms. Annu Rev Genomics Hum Genet 2001; 2: 235–258.
Get PDF (837K)